Terms: = Lung cancer AND ALK, CD246, ENSG00000171094, 238, Q9UM73, TFG/ALK
4958 results:
1. The cost-effectiveness of iruplinalkib versus alectinib in anaplastic lymphoma kinase-positive crizotinib-resistant advanced non-small-cell lung cancer patients in China.
Dai Z; Xu J; Chang F; Zhou W; Ren T; Qiu J; Lu Y; Lu Y
Front Public Health; 2024; 12():1333487. PubMed ID: 38699428
[TBL] [Abstract] [Full Text] [Related]
2. The relative risk of immune checkpoint inhibitor pneumonitis in advanced non-small- cell lung cancer: Meta-analyses of controlled clinical trials.
Kong Y; Hong L; Xu XC; Chen YF; Xu J
PLoS One; 2024; 19(4):e0301931. PubMed ID: 38683829
[TBL] [Abstract] [Full Text] [Related]
3. Prognostic importance of prognostic nutritional index and modified Glasgow prognostic score in advanced lung cancer with targetable mutation.
Bilgin B; Kuralay Y; Yucel S
J Cancer Res Clin Oncol; 2024 Apr; 150(4):215. PubMed ID: 38668879
[TBL] [Abstract] [Full Text] [Related]
4. Comprehensive genomic profiling of pulmonary spindle cell carcinoma using tissue and plasma samples: insights from a real-world cohort analysis.
Sun Y; Qin S; Wang S; Pang J; Ou Q; Liang W; Zhong H
J Pathol Clin Res; 2024 May; 10(3):e12375. PubMed ID: 38661052
[TBL] [Abstract] [Full Text] [Related]
5. Neoadjuvant EGFR-TKI therapy in Non-Small cell lung cancer.
Grant C; Nagasaka M
Cancer Treat Rev; 2024 May; 126():102724. PubMed ID: 38636443
[TBL] [Abstract] [Full Text] [Related]
6. Superparamagnetic Iron Oxide Nanoparticles Reprogram the Tumor Microenvironment and Reduce lung cancer Regrowth after Crizotinib Treatment.
Horvat NK; Chocarro S; Marques O; Bauer TA; Qiu R; Diaz-Jimenez A; Helm B; Chen Y; Sawall S; Sparla R; Su L; Klingmüller U; Barz M; Hentze MW; Sotillo R; Muckenthaler MU
ACS Nano; 2024 Apr; 18(17):11025-11041. PubMed ID: 38626916
[TBL] [Abstract] [Full Text] [Related]
7. Comparative study of imaging and pathology of primary mucinous adenocarcinoma with different imaging manifestations.
Han J; Gao J; Chen D; Du M; Wu Y; Ma X; Xie M; Han H; Wu C; Xue X
Clin Respir J; 2024 Apr; 18(4):e13750. PubMed ID: 38616354
[TBL] [Abstract] [Full Text] [Related]
8. Development of crizotinib-associated renal cyst in a non-small cell lung cancer patient with alk fusion: a case report and review of the literature.
Zhang P; Xu J; Wu Q; Qian J; Wang S
Diagn Pathol; 2024 Apr; 19(1):58. PubMed ID: 38616252
[TBL] [Abstract] [Full Text] [Related]
9. Proteogenomic Characterization Reveals Estrogen Signaling as a Target for Never-Smoker lung Adenocarcinoma Patients without EGFR or alk Alterations.
Park SJ; Ju S; Goh SH; Yoon BH; Park JL; Kim JH; Lee S; Lee SJ; Kwon Y; Lee W; Park KC; Lee GK; Park SY; Kim S; Kim SY; Han JY; Lee C
Cancer Res; 2024 May; 84(9):1491-1503. PubMed ID: 38607364
[TBL] [Abstract] [Full Text] [Related]
10. Targeted therapeutic options in early and metastatic NSCLC-overview.
Gálffy G; Morócz É; Korompay R; Hécz R; Bujdosó R; Puskás R; Lovas T; Gáspár E; Yahya K; Király P; Lohinai Z
Pathol Oncol Res; 2024; 30():1611715. PubMed ID: 38605928
[TBL] [Abstract] [Full Text] [Related]
11. Precision nanomedicine to treat non-small cell lung cancer.
Dessai A; Nayak UY; Nayak Y
Life Sci; 2024 Jun; 346():122614. PubMed ID: 38604287
[TBL] [Abstract] [Full Text] [Related]
12. [A case of crizotinib-associated renal cysts].
Quan LL; Huang P; Liang YC; Chen FW; Liu SB; Xin WW
Zhonghua Jie He He Hu Xi Za Zhi; 2024 Apr; 47(4):356-359. PubMed ID: 38599812
[TBL] [Abstract] [Full Text] [Related]
13. Alectinib in Resected
Wu YL; Dziadziuszko R; Ahn JS; Barlesi F; Nishio M; Lee DH; Lee JS; Zhong W; Horinouchi H; Mao W; Hochmair M; de Marinis F; Migliorino MR; Bondarenko I; Lu S; Wang Q; Ochi Lohmann T; Xu T; Cardona A; Ruf T; Noe J; Solomon BJ;
N Engl J Med; 2024 Apr; 390(14):1265-1276. PubMed ID: 38598794
[TBL] [Abstract] [Full Text] [Related]
14. Anaplastic lymphoma kinase-positive pulmonary inflammatory myofibroblastic tumour: a case report.
Tong D; Chisholm J; Madden B; Ahmed M
J Med Case Rep; 2024 Apr; 18(1):167. PubMed ID: 38594735
[TBL] [Abstract] [Full Text] [Related]
15. LTK mutations responsible for resistance to lorlatinib in non-small cell lung cancer harboring CLIP1-LTK fusion.
Mori S; Izumi H; Araki M; Liu J; Tanaka Y; Kagawa Y; Sagae Y; Ma B; Isaka Y; Sasakura Y; Kumagai S; Sakae Y; Tanaka K; Shibata Y; Udagawa H; Matsumoto S; Yoh K; Okuno Y; Goto K; Kobayashi SS
Commun Biol; 2024 Apr; 7(1):412. PubMed ID: 38575808
[TBL] [Abstract] [Full Text] [Related]
16. New Treatment Options for Patients With Oncogene-Addicted Non-Small Cell lung cancer Focusing on
Saw SPL; Le X; Hendriks LEL; Remon J
Am Soc Clin Oncol Educ Book; 2024 Apr; 44(3):e432516. PubMed ID: 38560815
[TBL] [Abstract] [Full Text] [Related]
17. The prognostic value and model construction of inflammatory markers for patients with non-small cell lung cancer.
Xu W; Liu X; Yan C; Abdurahmane G; Lazibiek J; Zhang Y; Cao M
Sci Rep; 2024 Mar; 14(1):7568. PubMed ID: 38555313
[TBL] [Abstract] [Full Text] [Related]
18. Biomarker Turnaround Times and Impact on Treatment Decisions in Patients with Advanced Non-Small Cell lung Carcinoma at a Large Canadian Community Hospital with an Affiliated Regional cancer Centre.
Fleming KE; Hupel A; Mithoowani H; Lulic-Kuryllo T; Valdes M
Curr Oncol; 2024 Mar; 31(3):1515-1528. PubMed ID: 38534948
[No Abstract] [Full Text] [Related]
19. Treating anaplastic lymphoma kinase (alk) fusion-driven metastatic non-small cell lung cancer (NSCLC) with alectinib through pregnancy.
Wu F; Rittberg R; Lim K; Ho C
BMJ Case Rep; 2024 Mar; 17(3):. PubMed ID: 38531551
[TBL] [Abstract] [Full Text] [Related]
20. If it's a target, it's a pan-cancer target: Tissue is not the issue.
Adashek JJ; Kato S; Sicklick JK; Lippman SM; Kurzrock R
Cancer Treat Rev; 2024 Apr; 125():102721. PubMed ID: 38522181
[TBL] [Abstract] [Full Text] [Related]
[Next]
